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Context: Thrombophilia is an inherited or acquired predisposition in 
developing thrombosis. The two common thrombophilia polymorphisms are 
factor V Leiden (FVL) and factor II/ prothrombin G20210A (PT) gene 
mutations which can contribute to negative pregnancy outcomes such as 
miscarriage, in-vitro fertilization (IVF) failure, preeclampsia, intrauterine 
growth restriction (IUGR), placental abruption, stillbirth, and pregnancy-
associated venous thromboembolism. This review study sought to describe the 
effects of FVL and PT mutations on pregnancy complications. 
Evidence Acquisition: In this review study, a comprehensive search was 
performed on Iranian and international databases including MEDLINE, 
PubMed, Scopus, Web of Sciences, Proquest and Google Scholar for articles 
published during 1996-2018. Out of 220 reviewed articles, 80 papers were 
ultimately selected. 
Results: According to these 80 selected papers, the possible relations of PT 
and FVL with recurrent pregnancy loss (RPL) have been widely evaluated. 
Several studies indicated higher risk of recurrent early miscarriages, 
implantation failure and fetal loss after IVF among women with FVL and PT 
mutations. 
Conclusion: Observational studies have suggested the benefits of screening 
patients for thrombophilic polymorphisms in identification of women with 
higher risk of developing thromboembolic events and other related pregnancy 
complications. Based on such screening programs, prophylactic therapy can be 
limited to a selected group of women who truly need it. 
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     Thrombophilia is an inherited or 
acquired predisposition in developing either 
venous or arterial thrombosis. Thrombosis 
is a common cause of death in the U.S. 
[1].The combined prevalence of different 
types of thrombophilia in the general 
population exceeds one in ten. The most 
commonly reported type of acquired 
thrombophilia is the antiphospholipid 
syndrome (APS). The diagnostic criteria for 
this condition are presence of 
antiphospholipid antibodies consisting anti-
cardiolipin antibodies (aCL) and/or lupus 
anticoagulant (LA); and/or anti-ᵦ-2-
glycoprotein I antibodies (aᵦ2-GPI)  for two 
or more separate occasions, at least 12 
weeks apart [2]. Inherited risk factors of 
thrombophilia include protein C, protein S, 
and antithrombin (AT III) deficiency, 
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Factor V Leiden (FVL), and prothrombin 
G20210A (PT) gene mutations [3, 4]. FVL 
and PT may cause miscarriage, 
preeclampsia, intrauterine growth 
restriction
1
, placental abruption, and 
stillbirth in pregnant women [5, 6]. 
Thrombophilic disorders are in fact believed 
to exacerbate the state of hypercoagulability 
in pregnancy and lead to the formation of 
microthrombin and placental insufficiency 
[7]. 
Thrombophilia is a complex disorder with 
various risk factors. The most commonly 
reported form of acquired thrombophilia is 
the APS. FVL, i.e. the underlying cause of 
activated protein C resistance and PT are 
considered as two major genetic risk factors 
for the condition. Despite their significance, 
these two factors generally remain 
underdiagnosed due to the absence of 
symptoms and low risk of thrombosis in 
their carriers. Nevertheless, the presence of 
the mentioned factors may become 
clinically evident following exposure to 
other predisposing factors including 
pregnancy, oral contraceptives, hormone 
replacement therapy, and vessel wall 
disorders which encourage stasis and boost 
the risk of life-threatening thrombotic 
events [6]. Extensive research over the past 
50 years has confirmed significant 
relationships between thrombophilia (both 
inherited and acquired) and elevated risk of 
serious obstetric complications such as 
miscarriage, stillbirth, severe preeclampsia, 
placental abruption, IUGR, and other 
adverse obstetric outcomes. Although the 
exact involved mechanisms are unknown, 
inadequate maternal-fetal circulation and 
decreased placental perfusion caused by 
abnormal placental vasculature and 
disturbances in hemostasis might be 
responsible for the mentioned complications 
[8].Since higher frequency of FVL, PT, and 
methylene tetrahydrofolate reductase 
(MTHFR) C677T mutations has been 
documented in women with such 
                                                           
1 IUGR 
complications[9]. Based on the results of 
previous studies, the rates of preterm births 
have increased over time. Furthermore, 
thrombophilia may have negative impacts 
on pregnancy outcomes, especially preterm 
birth and the consequent neonatal and 
childhood injuries and deaths, and exert a 
heavy economic burden on society and 
families. 
Hence, the present study aimed to estimate 
the prevalence of FVL and PT in women 
with pregnancy complications such as: 
preterm birth, recurrent pregnancy loss 
(RPL), and other pregnancy complications. 
It will thus provide the chance to determine 
the pathogenesis of this condition. 
 
2. Evidence Acquisition 
     In this review study, a comprehensive 
search was performed on several international 
databases including PubMed, EMBASE, ISI 
Web of Science, Scopus, and Google Scholar 
along with Iranian databases such IranMedex, 
Magiran, and Scientific Information 
Database. Boolean operators (OR, AND) 
were applied to produce combinations of 
appropriate keywords (i.e. factor V Leiden, 
prothrombin G20210A, factor II, mutation, 
pregnancy complications). Using advanced 
search options of each search engine, articles 
were retrieved if they were published during 
1996-2018 and had one of the first four 
keywords in either their title or their abstract. 
The only inclusion criterion was dealing 
explicitly with FVL and PT in women with 
pregnancy complications. Hence papers in 
English and Persian languages were surveyed 
if they reported effect of FVL and PT 
mutations on pregnancy complications and 
studies without quantitative outcome data 
were excluded. The reference list of the 
retrieved papers was inspected and searched 
over other search engines. The algorithm of 
the including studies in our review is shown 
in Figure 1 (Figure 1). 
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Figure 1. The algorithm of including studies in the review
3. Results 
     While the initial search yielded 220 
articles, the number was reduced to 80 after 
eliminating duplicate or irrelevant papers 
(based on the number of citations). The role 
of Factor V Leiden and Prothrombin 
mutations in pregnancy complications are 
described in this section: 
 
1. Factor V Leiden (FVL) 
     FVL is an inherited autosomal dominant 
trait [10]. It involves a guanine to adenine 
substitution at nucleotide position 1691 in 
the factor V gene. The result would be a 
defective factor V molecule, called FVL, 
which is intrinsically resistant to cleavage 
by activated protein C (APC) [6]. 
Therefore, the disorder is characterized by a 
poor functional resistance of coagulation 
factor V to APC. FVL is the most frequent 
hereditary cause of venous thrombosis and 
is in fact 10 times more frequent than any 
other anticoagulant protein deficiency. The 
condition accounts for about 20%-25% of 
all thrombotic events and 40%-45% of 
cases of hereditary thrombophilia [11]. 
Zygosity can also have significant effects 
on the risk of venous thrombosis, i.e. 
heterozygosity and homozygosity, as FVL 
increases the risk of the condition by three 
to ten- and eighty to one-hundred-folds, 
respectively. FVL is believed to have 
emerged about 21000-34000 years ago 
when Caucasians separated from Asians 
[12]. The prevalence of FVL in 
thrombophilic patients has been reported as 
about 3.3% in Iran and 2.5% in Saudi 
Arabia. However, the exact prevalence of 
the mutation in the general population is 
still not clear [13]. In a systematic review of 
14 studies, it was observed that the effect of 
FVL mutation on spontaneous abortions and 
IVF failures was confirmed by all of the 
studies, while there was no observed 
relationship between FVL mutation with 
IUGR, preeclampsia, placental abruption or 
small for gestational age newborns 
(SGA)[14]. 
 
2. Prothrombin G20210A 
     Prothrombin (factor II) is the precursor 
of thrombin. PT involves a guanine to 
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adenine transition at position 20210 of the 
prothrombin gene. It is an autosomal 
dominant trait and the second most 
prevalent genetic cause of thrombophilia 
[15]. It increases plasma levels of 
prothrombin and the risk of venous or 
arterial thrombosis, thromboembolic disease 
and severe subsequent IUGR, preeclampsia, 
placental abruption, and preterm labor[16]. 
The frequency of PT varies in different 
societies. It is more prevalent in the Middle 
East, but is rare in other Asian countries 
such as Japan[17]. The prevalence of PT 
was reported as 0.02% and 1%-4% in black 
and white patients, respectively. Moreover, 
the prevalence of FVL and PT among 
healthy Iranians was estimated at 2.9% and 
1.6%, respectively[18]. Gawish introduced 
PT and FVL as crucial risk factors for 
neonatal stroke in Saudi newborns and 
recommended their monitoring as a part of 
routine tests for Saudi fetuses and pregnant 
women[6].The risk of thrombosis among 
heterozygous carriers have a five to ten-fold 
increased risk of FVL and homozygotes 
have a fifty to one-hundred-fold increased 
risk. The risk of thrombosis is also three to 
ten times higher in individuals heterozygous 
for PT [19]. Inherited risk factors, e.g. 
genetic defects such as PT G20210A and 
external factors such as oral contraceptives, 
pregnancy, surgical procedures, prolonged 
immobilization, aging, HRT, malignancies, 
obesity, prolonged catheterization, and 
inflammatory conditions seem to elevate the 
risk of thrombosis. These factors are often 
necessary for symptomatic carriers of FVL 
[20, 21]. While numerous studies have tried 
to shed light on the association between 
different polymorphisms and pregnancy 
complications including miscarriage, 
preeclampsia, and IUGR, limited research 
has focused on thrombophilia [22]. Kocher 
et al. established a relation between PT and 
preterm delivery among white women [10]. 
Uvuzetal., however, refuted a significant 
association between preterm delivery and 
thrombophilic gene polymorphisms [22]. 
 
3. Pregnancy Complications 
3.1 Recurrent Pregnancy Loss (RPL) 
     RPL is a prevalent disturbing health 
issue. While it is classically defined as the 
loss of three or more consecutive 
pregnancies before the fetus has reached 
viability (affecting 1-2% of women), the 
term has been recently redefined to include 
two or more losses (thus present in over 5% 
of reproductive women). Although the 
cause of up to 50% of these cases remain 
unexplained [23-25], thrombophilia has 
been suggested as a probable cause of 
RPL[3]. Several studies have shown higher 
risk of recurrent early miscarriages, second-
trimester abortion, or other complications in 
women with inherited thrombophilia. 
Thrombophilia is in fact responsible for up 
to 40% of RPL cases and the second cause 
of the condition (after chromosomal 
abnormalities), particularly in the first four 
months of pregnancy. During the past two 
decades, research has confirmed a 
significant relationship between RPL and 
antiphospholipid syndrome (APS) which is 
an acquired thrombophilic state[25]. 
According to recent studies, certain types of 
inherited thrombophilia, such as FVL and 
PT are more common in women with 
unexplained RPL[26]. Among all 
thrombophilic mutations, the relations of PT 
and FVL with the incidence of RPL have 
been more widely studied [27]. 
In 2000, a Greek study recruited 80 women 
with RPL and 100 healthy controls to 
identify any possible associations between 
RPL and FVL, PT, and MTHFR C677T 
mutations. FVL and PT was found in about 
25% of women with a history of fetal loss 
(regardless of the presence of additional 
pathologies) and concluded that these two 
mutations (but not MTHFR 
C677Thomozygosity) could be risk factors 
for RPL. Furthermore, the prevalence of the 
mentioned mutations was high in women 
with second trimester pregnancy loss (40%) 
and primary fetal loss (33%). Both FVL and 
PT served as dramatic predisposing factors 
when primary RPL was involved 
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[11].Mohamed et al. reported significantly 
higher prevalence of spontaneous 
miscarriages in women with FVL, PT, and 
MTHFR gene mutations compared to the 
normal population [28]. 
While FVL is rare in Asians and Africans, it 
is more common in European populations 
(5%-9% of healthy individuals) [12, 29]. A 
meta-analysis suggested that race 
significantly affects the association between 
FVL and RPL [30]. Another nested case-
control study on Caucasian women from a 
delimited Mediterranean area indicated 
FVL and PT to have significant relations 
with the risk of spontaneous abortion 
occurring from the 10th week of the first 
intended pregnancy on. However, no clear 
conclusions could be reached about non-
Caucasian women in whom the frequency 
of thrombophilic mutations was 
substantially low [31]. In contrast, some 
researchers did not accept FVL as a risk 
factor for RPL. For instance, according to 
an Iranian case-control study, FVL and PT 
were not frequently found in women with 
RPL [32]. Another retrospective case-
control study found no significant 
differences in the allele frequencies and 
genotype distribution for FVL and PT gene 
polymorphisms between patients with RPL 
and controls. It also refuted any significant 
relationships between the mentioned factors 
and infertility (except an increased 
frequency of association between the two 
gene polymorphism AA 
G1691A/GAG20210A and GA 
G1691A/GG G20210A compared to the 
control group) [33]. Meanwhile, early 
abortion cases were more frequent among 
women with heterozygous PT G20210A 
than in those with heterozygous FVL (28% 
vs. 16%). Although similar findings were 
reported in cases with either late or 
combined late and early miscarriage, the 
difference was not statistically significant. 
The same study showed a very high risk of 
pregnancy loss among patients carrying 
both genotypes, i.e. the mutant allele of 
FVL and prothrombin. The researchers 
hence concluded that RPL among Saudi 
women was strongly associated with 
thrombophilic mutations related to both 
FVL and PT[6]. 
Goodman et al. reported significantly higher 
frequency of FVL and PT gene mutations 
among American women with a history of 
RPL[34]. In contrast, another study on a 
similar population of American women did 
not detect any differences in the frequency 
of definite FVL or PT gene mutations. 
Nevertheless, significantly higher 
prevalence of homozygous mutations and 
total gene mutations was observed in 
patients with RPL than in controls [35]. 
Some studies have rejected any significant 
associations between the two frequent 
thrombophilic mutations (FVL and PT) and 
RPL. These studies, however, have 
documented higher APCR (but not 
significantly) in subjects with RPL than in 
healthy women. Meanwhile, the higher 
prevalence of vascular complications in 
women with FVL seems reasonable since 
APC sensitivity ratios may be reduced 
during a normal pregnancy even in women 
with normal factor V genotype[27]. 
Previous meta-analyses introduced FVL and 
PT as the only thrombophilic mutations 
involved in RPL[36, 37]. Di Micco et al. 
suggested inherited thrombophilia, 
especially the PT variant, as a risk factor for 
RPL[38]. However, the absence of any 
relationships between RPL and the 
mentioned prothrombotic states has been 
discussed in some other studies[39, 40]. 
As discussed earlier, the frequency of 
thrombophilic mutations varies in different 
ethnic groups and societies. Therefore, 
researchers from different parts of the world 
have tried to shed light on the relationships 
between inherited thrombophilia and RPL 
in different populations. A case control 
study in Colombia, i.e. a tri-ethnic 
population comprising about 70% 
Caucasians, 15% Amerindians, and 15% 
Africans[41, 42] found no associations 
between RPL and hereditary thrombophilia 
by either single nucleotide polymorphism 
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(SNP) genotypes, such as FVL, PT, and 
MTHFR C677T, or functional phenotypes, 
e.g. APCR and protein C and AT III 
deficiency. Considering the negligible 
frequency of thrombophilia associated 
SNPs in not only the controls, but also the 
patients, the researchers concluded that 
testing for hereditary thrombophilia was 
unnecessary in the initial evaluation of 
patients with RPL [43]. Similarly, FVL and 
PT were rarely detected in Malay women 
with RPL [44].On the other hand, Brazilian 
FVL carriers had a 4.9 times higher risk of 
RPL than their non-carrier counterparts. 
Likewise, the risk of RPL was five times 
higher in Uruguayan women heterozygous 
for FVL than in non-carriers[45]. Two 
prospective cohort studies have also 
reported the absence of any associations 
between hereditary thrombophilia and RPL 
[43]. Kazerooni et al. detected elevated 
levels of thrombophilic parameters in 
patients with a combination of polycystic 
ovary syndrome (PCOS) and RPL. They 
also found FVL mutations to be more 
frequent in these individuals than in PCOS 
patients without RPL. They hence 
highlighted associations between increased 
RPL rates and hyperhomocysteinemia, 
APCR, and FVL in patients with PCOS 
[46].A case-control study in Portugal 
negated any relations between either FVL 
or PT and RPL during the first 10 weeks of 
gestation. It thus concluded that testing for 
these mutations in the initial screening of 
women with RPL and negative personal 
thromboembolic history was not cost-
effective [25]. Similarly, in a controlled 
study, Dilley et al. found the frequency of 
FVL and PT to be similar in 60 women with 
RPL and 92 controls without a history of 
miscarriage [47]. Two prospective 
multicenter studies on over 4,000 pregnant 
women during their first trimester did not 
show an increased miscarriage rate in FVL 
and PT carriers [48]. A European 
prospective research on women with a 
history of miscarriage reported no 
significant differences in pregnancy 
outcomes between carriers and non-carriers 
of FVL and PT[49]. 
Controlled studies on European Caucasian 
women with a history of unexplained RPL 
could not establish a relationship between 
RPL in the first trimester and either FVL or 
PT [50, 51]. Meanwhile, previous meta-
analyses have suggested FVL-related losses 
to be more common after the 14th week 
than in the first trimester [36, 52].  In a 
study on Caucasian women with 
unexplained RPL, Ivanov et al. found FVL 
to have a similar prevalence in subjects with 
embryonic losses and controls (9.6% vs. 
7.0%). In contrast, FVL was more prevalent 
(18.6%) in women who experienced 
pregnancy losses during the10th-14th weeks 
of gestation[53]. 
Considering the controversial results of 
previous studies, clinicians prefer to 
incorporate FVL and PT tests in RPL 
investigation protocols[52, 54]. However, 
while evidence about the relations between 
these two mutations and RPL stem from 
case-control studies [55, 56],  such studies 
might have been biased by various factors 
[48]. Nonetheless, most studies have 
reported similar findings about the 
association between these two mutations 
and RPL. Moreover, the associations 
between the mentioned polymorphisms and 
RPL seem to be weaker in cases of first 
trimester loss compared to second trimester 
RPL [30]. Apparently, the exact effect of 
hereditary thrombophilia on RPL is still a 
controversial issue. Recent research has in 
fact led to greater uncertainty about the 
existence of an association between the 
mentioned conditions[57, 58]. One small 
study reported the frequency of PT in 
subjects with RPL and controls as 9% and 
2%, respectively[11]. Another case-control 
study consisting of 102 patients with two or 
more consecutive abortions and 128 women 
without miscarriage calculated the rates 
among women with RPL and controls as 
6.7% vs. 0.8% respectively [59]. Due to 
lack of adequate evidence, recent guidelines 
on the assessment and management of 
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women with RPL, published by the Royal 
College of Obstetricians and Gynecologist 
and the American College of Obstetricians 
and Gynecologists do not assert the need for 
routine thrombophilia screening and 
anticoagulant therapy [60]. 
 
3.2 Placental-Mediated Pregnancy 
Complications 
     Pregnancy loss, preeclampsia, placental 
abruption, and birth of small for gestational 
age (SGA) infants are stressful and 
catastrophic events for not only women and 
their families, but also the whole society 
[61].While a successful pregnancy requires 
adequate placental circulation, 
thrombophilia is believed to increase the 
risk of placental insufficiency through 
micro- and/or macro-vascular placental 
thrombosis and negative impacts on 
trophoblastic growth and differentiation. 
There have also been debates over the 
possible role of FVL and PT in implantation 
failure and fetal loss after in vitro 
fertilization (IVF) [62]. 
 
3.3 IVF Failure 
     The critical role of FVL in embryonic 
implantation and cell adhesion, smooth 
muscle cell proliferation, and 
vasculogenesis during fetal development 
has been confirmed. Roqué et al. identified 
the benefits of FVL in facilitating 
embryonic implantation [63, 64]. In fact, the 
existence of FVL in either the mother or the 
infant has been associated with higher 
implantation rates in pregnancies resulting 
from intracytoplasmic sperm injection 
(ICSI)[65]. About one-third of women 
undergoing IVF will achieve a successful 
pregnancy[66]. 
However, the success of embryo transfer 
after IVF depends on several factors 
including inherited or acquired 
thrombophilia. Thrombophilia is known to 
disturb the angiogenesis and vasculogenesis 
(required for a successful pregnancy) and 
thus contribute to early pregnancy loss and 
implantation failure [67]. Thrombosis or 
infarcts in the placental sections may imply 
a hemostatic abnormality caused by 
thrombophilia [68]. Significantly higher 
rates of pregnancy loss have been found in 
heterozygous and/or homozygous carriers 
of FVL, PT, and MTHFR gene mutations 
compared to their control counterparts. Al 
Husseini et al. confirmed an association 
between the presence of FVL and higher 
rates of fetal loss following IVF [69]. 
Similarly Azem et al. suggested higher 
frequency of thrombophilia in subjects with 
recurrent IVF-embryo transfer failure than 
in those without such an experience [70]. 
Qublan et al. reported FVL to be more 
common in women with recurrent IVF 
failure than in subjects with successful IVF 
experience and healthy women [67]. 
Moreover, microthrombosis at the 
implantation site may alter the invasion of 
syncytiotrophoblast to mother’s vessels and 
lead to implantation failure or fetal loss. In 
fact, the existence of at least one 
thrombophilic factor has been proved in 
female patients with recurrent IVF-embryo 
transfer failures[70].On the other hand, 
following the detection of greater ICSI 
success in FVL carriers, Göpel et al. 
concluded that the thrombotic tendency in 
mothers with FVL mutation promoted 
successful fetal implantation [65]. However, 
significantly higher frequency of PT has 
been discovered in women with IVF 
pregnancy loss than in their control 
counterparts [11]. Rey et al. suggested PT 
mutation to double or triple the risk of RPL 
after IVF [37]. Colman et al. compared 
healthy fertile women with those 
experiencing recurrent implantation failure 
and highlighted the presence of at least 
three gene mutations in the latter group 
[35]. In a study performed for the purpose 
of examining the relationship between 
undiagnosed thrombophilic factors and IVF 
failure, Qublan et al. compared 90 women 
with more than two consecutive failed IVF 
attempts (group A) and two control groups 
(group B and C). The first control group 
(group B) comprised of 90 women whose 
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first IVF embryo transfer led to successful 
pregnancy. The second control group 
(group C) consisted of 100 women with 
spontaneous conception, at least one 
unsuccessful pregnancy, and no history of 
miscarriage. The researchers found higher 
frequency of FVL in group A (14.4%) than 
in groups B(1%) and C (2%) [67]. While 
Grandone et al. published similar findings 
[71], other researchers have generally failed 
to establish such an association[70], though 
it seems that the results of past studies 
support negative roles of these two gene 
mutations in IVF outcomes. In conclusion, 
more experimental studies are 
recommended to confirm the 
ineffectiveness of these two polymorphisms 
on IVF outcomes. 
 
3.4 Preeclampsia 
     Preeclampsia is a multisystem vascular 
disorder affecting 5%-8% of pregnant 
women in the second half of gestation, 
which is one of the major causes of 
maternal and perinatal morbidity and 
mortality [72, 73]. A cumulative meta-
analysis of prospective cohort studies 
estimated the prevalence of PT gene 
mutation among over 9000 women at 2.9%. 
However, no significant relation could be 
established between this mutation and 
preeclampsia[61]. Meanwhile, the European 
Prospective Cohort on Thrombophilia 
(EPCOT) suggested significantly higher 
frequency of stillbirth,  preeclampsia, and 
placental abruption among FVL carriers 
[74]. Moreover, significant relations have 
been documented between severe 
preeclampsia and FVL mutation, 
hyperhomocysteinemia, AT III and proteins 
S and C deficiencies [8]. 
 
3.5 Preterm Birth 
     Preterm birth, defined as childbirth 
before 37 weeks of gestation, is associated 
with high levels of long-term health 
consequences [72, 75], mortality, and 
morbidity in neonates and infants [76]. A 
single-center case-control study on women 
with preterm infants (born before 36 weeks 
of gestation) rejected any significant 
relations between three common 
thrombophilic polymorphisms (FVL, PT, 
and MTHFR) and preterm birth of unknown 
cause, history of abortion, and venous 
thrombosis. In addition, the preterm and 
term infants were not significantly different 
in the frequency of the mentioned gene 
mutations [77]. Nevertheless, in a cohort of 
205 low birth weight (LBW) infants, Göpel 
et al. reported prematurity to be 
significantly associated with both FVL and 
PT. They, however, failed to confirm the 
observed association in another population 
(n =102) of preterm infants of multiple 
pregnancies [78]. Silver et al. conducted a 
prospective cohort of over 4,000 low-risk 
women. They did not notice any significant 
relationships between PT and either 
gestational age at delivery or obstetric 
complications such as pregnancy loss, 
preeclampsia, placental abruption, and SGA 
neonates [48]. 
 
3.6 Intrauterine Growth Restriction 
(IUGR) 
     There is little evidence to suggest a 
relationship between IUGR and 
thrombophilia [8]. A retrospective study on 
the prothrombotic risk factors of IUGR in 
Germany revealed that inherited risk 
factors, particularly FVL, boosted the risk 
of LBW. The effect was more noticeable in 
children with either homozygous or 
combined prothrombotic defects [79]. In a 
very large study, Infante-Rivard et al. 
refuted the idea that inherited thrombophilia 
served as a clinically significant cause of 
IUGR [80]. 
 
3.7 Thromboprophylaxis in 
Pregnancy 
     Prophylaxis with low-molecular-weight 
heparin (LMWH) and unfractionated 
heparin (UFH), with or without aspirin, has 
been suggested to prevent poor pregnancy 
outcome in women with gestational 
vascular complications and history of 
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pregnancy-related complications [51]. 
However, as prophylactic therapy may not 
be required in all pregnant women, 
identification of high-risk patients through 
screening for thrombophilic polymorphisms 
can limit the treatment to a specific group 
[81]. A recent prospective observational 
study found that the odds of preeclampsia, 
intrauterine fetal death (IUFD), placental 
abruption, or venous thromboembolism 
were not higher in heterozygous carriers of 
FVL mutation. Nevertheless, these results 
may not be generalizable since almost 50% 
of the studied patients had been treated with 
heparin. Based on previous research, 
women with RPL, placental abruption, 
preeclampsia, infertility, implantation 
failures, IVF-embryo transfer failures, 
thromboembolic disease at a young age and 
without a particular cause, a family history 
of venous thromboembolism (a first-degree 
relative before the age of 50 years), or 
thrombosis in an unusual site should be 
investigated for thrombophilia. FVL 
evaluations are particularly important in 
these patients because the mentioned gene 
mutation confers a higher risk of not only 
venous thromboembolism, but also obstetric 
complications    [39, 53, 82]. In a Cochrane 
review,  Empson et al. evaluated 13 trials 
performed on a total number of 849 women. 
They confirmed that a combination of 
aspirin and UFH could decrease pregnancy 
loss by 54% [83]. Kupferminc et al. 
conducted a case-control study in 2011 and 
found the risk of stillbirth, placental 
abruption, and preeclampsia to be higher in 
women with thrombophilia. They concluded 
that LMWH treatment of women with 
previous severe pregnancy complications 
and thrombophilias significantly reduces the 
rate of recurrence. Hence they suggested 
heparin as an effective measure to both 
prevent and treat the mentioned conditions 
[7]. Prophylactic administration of LMWH 
was also reported to successfully decrease 
the risk of obstetric complications in female 
carriers of FVL or PT who had a history of 
pregnancy complications [84]. While 
LMWH is as effective as UFH, it is safer 
and associated with lower risk of 
developing heparin-induced 
thrombocytopenia. Moreover, cases of 
osteoporosis and fracture formation have 
been reported in pregnant women who were 
exposed to UFH for long periods of time 
[85]. In women with antiphospholipid 
syndrome, guidelines recommend 
prescribing aspirin and heparin to women 
with recurrent miscarriage. Aspirin or 
LMWH to improve pregnancy outcome in 
women with unexplained recurrent 
miscarriage has no benefit and should not 
be prescribed. Whether anticoagulant 
therapy prevents recurrent miscarriages in 
women with inherited thrombophilia or in 
women with severe pregnancy 
complications remains controversial 




      Based on the present review, evidence 
indicated higher risk of recurrent early 
miscarriages, implantation failure and fetal 
loss after IVF among women with FVL and 
PT mutations. So screening patients for 
thrombophilic polymorphisms in 
identification of high risk women for 
developing thromboembolic events and 
other related pregnancy complications is 
beneficial. It would determine the target 
group for prophylactic therapy 
Since the outbreak of all types of 
thrombophilic states including inherited 
(such as PT and FVL) and acquired (such as 
APS) in women with pregnancy 
complications is not so infrequent, every 
specialist should consider these conditions 
and investigate them in their patients with 
recurrent fetal loss or severe complication 
of the pregnancy. The most commonly 
reported type of acquired thrombophilia is 
the antiphospholipid syndrome (APS). Of 
women with recurrent pregnancy loss, 
10%–20% have detectable aPL. A meta-
analysis done by Abou-Nassar concluded 
that antiphospholipid antibodies appear to 
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be most consistently associated with late 
fetal loss, with LA being the strongest and 
most consistent antibody associated with 
placenta mediated pregnancy complications 
(87). PT and FVL are the most extensively 
studied thrombophilic mutations in 
association with RPL. Several studies have 
shown that women with inherited 
thrombophilia, such as FVL and PT 
mutations carry a higher chance for 
recurrent early miscarriages and second 
trimester abortion. Heterozygosity for FVL 
or PT gene mutation increases the risk of 
venous thromboembolism during 
pregnancy, implantation failure, and fetal 
loss after IVF. However, one study 
suggested higher ICSI success in mothers 
with FVL and suggested the thrombotic 
tendency in FVL carriers to have some 
advantages in fetal implantation. While 
associations have been established between 
severe preeclampsia and FVL, 
hyperhomocysteinemia, and AT III and 
proteins S and C deficiencies, no such 
relations have been identified in case of PT. 
Moreover, there is still controversy over the 
effects of these two polymorphisms on 
preterm delivery. In fact, while some 
studies suggested similar gestational age at 
delivery among carriers and non-carriers of 
these mutations, a retrospective analysis 
demonstrated that inherited thrombophilia, 
mainly FVL, increased the risk of giving 
birth to LBW infants. In conclusion, 
according to previous research, screening 
patients for thrombophilic polymorphisms 
might be helpful in identifying patients with 
increased risk for thromboembolic events 
and other related adverse pregnancy 
outcomes. 
Furthermore, such screening would 
determine the target group for prophylactic 
therapy. Nevertheless, based on Royal 
College of Obstetricians and Gynecologists 
and the American College of Obstetricians 
and Gynecologists guidelines, there is still a 
lack of evidence in favor of routine 
thrombophilia screening and anticoagulant-
based interventions during pregnancy. 
Therefore, this study recommends that the 
screening for thrombophilias be 
encouraged. The study also suggests that 
LMWH treatment is more effective in 
reducing adverse pregnancy outcome in 
thrombophilias.  
The most major limitation of this study was 
that the authors did not systematically 
review all available studies. Therefore, it is 
recommended for other researchers to do a 
systematic review on these two factors in 
future. Regardless of the limitations of the 
current study, the authors  believe that the 
results emphasize the relevance of the topic 
of thrombophilias in pregnancy 
complications and point out the need for 
further research. 
    
5. Conclusion 
     According to our review, the possible 
relations of Factor V Leiden and 
Prothrombin G20210A Mutations with 
recurrent pregnancy loss have been widely 
evaluated. Several studies indicated higher 
risk of recurrent early miscarriages, 
implantation failure and fetal loss after IVF 
among women with FVL and PT mutations. 
Accordingly, studies have suggested the 
benefits of screening patients for 
thrombophilic polymorphisms in 
identification of women at higher risk of 
developing thromboembolic events and 
other related pregnancy complications. 
Furthermore, such screening would 
determine the target group for prophylactic 
therapy, who truly need it. 
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